Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.36 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4592415 | 1.00 | MCL1 (0.41) | MCL1NOTUMHMOX1KMT2ARAB9A | |
| Biphenyl SCHEMBL2202263 | 0.72 | NOTUM (0.44) | NOTUMHMOX1KMT2ARAB9ATP53 | |
| SCHEMBL918756 | 0.68 | NOTUM (0.47) | NOTUMHMOX1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL22471559 | 0.67 | KMT2A (0.56) | MCL1KMT2A | |
| SCHEMBL707611 | 0.66 | — | — | |
| SCHEMBL1502065 | 0.65 | KMT2A (0.50) | NOTUMKMT2ATP53SMN1; SMN2 | |
| SCHEMBL3079013 | 0.65 | TP53 (0.54) | KMT2ARAB9ATP53SMN1; SMN2 | |
| SCHEMBL23248712 | 0.65 | CHRM1 (0.58) | MCL1KMT2A | |
| SCHEMBL30491169 | 0.65 | RAB9A (0.55) | KMT2ARAB9ATP53SMN1; SMN2AKR1C3 | |
| SCHEMBL17397066 | 0.65 | MCL1 (0.57) | MCL1KMT2ATP53SMN1; SMN2AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362017-B2 | N-[5-chloro-2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide; antiproliferative agents; protein kinase inhibitors; drug screening | EXELIXIS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | KIT, PRKCH, PRKCB | MCL1 139/4885NOTUM 3734/4885HMOX1 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.